CoChat

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations

Open access
Bertoglio, Federico, Fühner, Viola, Ruschig, Maximilian, Heine, Philip Alexander, Abassi, Leila, Klünemann, Thomas, Rand, Ulfert, Meier, Doris, Langreder, Nora, Steinke, Stephan, Ballmann, Rico, Schneider, Kai-Thomas, Roth, Kristian Daniel Ralph, Kuhn, Philipp, Riese, Peggy, Schäckermann, Dorina, Korn, Janin, Koch, Allan, Chaudhry, M. Zeeshan, Eschke, Kathrin, Kim, Yeonsu, Zock-Emmenthal, Susanne, Becker, Marlies, Scholz, Margitta, Moreira, Gustavo Marçal Schmidt Garcia, Wenzel, Esther Veronika, Russo, Giulio, Garritsen, Hendrikus S.P., Casu, Sebastian, Gerstner, Andreas, Roth, Günter, Adler, Julia, Trimpert, Jakob, Hermann, Andreas, Schirrmann, Thomas, Dübel, Stefan, Frenzel, André, Van den Heuvel, Joop, Čičin-Šain, Luka, Schubert, Maren, Hust, Michael · 2021 · Cell Reports

Published version of a preprint

Cited by 96

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

in a plaque-based live SARS-CoV-2 neutralization assay. The in vivo efficacy of the antibody is demonstrated in the Syrian hamster and in the human angiotensin-converting enzyme 2 (hACE2) mice model. The crystal structure of STE90-C11 Fab in complex with SARS-CoV-2-RBD is solved at 2.0 Å resolution showing that the antibody binds at the same region as ACE2 to RBD. The binding and inhibition of STE90-C11 is not blocked by many known emerging RBD mutations. STE90-C11-derived human IgG1 with FcγR-silenced Fc (COR-101) is undergoing Phase Ib/II clinical trials for the treatment of moderate to severe COVID-19.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2021.109433

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 75

  1. Lundgren, 2021, A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19, N. Engl. J. Med., 384, 905, 10.1056/NEJMoa2033130 · DOI · Paper page
  2. Alfaleh, 2020, Phage Display Derived Monoclonal Antibodies: From Bench to Bedside, Front. Immunol., 11, 1986, 10.3389/fimmu.2020.01986 · DOI · Paper page
  3. Annavajhala, 2021, A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York, medRxiv
  4. Armour, 1999, Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities, Eur. J. Immunol., 29, 2613, 10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J · DOI · Paper page
  5. Bertoglio, 2021, SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface, Nat. Commun., 12, 1577, 10.1038/s41467-021-21609-2 · DOI
  6. Boyerinas, 2015, Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells, Cancer Immunol. Res., 3, 1148, 10.1158/2326-6066.CIR-15-0059 · DOI · Paper page
  7. Bradbury, 2011, Beyond natural antibodies: the power of in vitro display technologies, Nat. Biotechnol., 29, 245, 10.1038/nbt.1791 · DOI · Paper page
  8. Brejová, 2021, B.1.258$∖Delta$, a SARS-CoV-2 variant with ΔH69/ΔV70 in the Spike protein circulating in the Czech Republic and Slovakia, arXiv
  9. Brünger, 1998, Crystallography & NMR system: a new software suite for macromolecular structure determination, Acta Crystallogr. D Biol. Crystallogr., 54, 905, 10.1107/S0907444998003254 · DOI · Paper page
  10. Burkhardt, 2016, Status of the crystallography beamlines at PETRA III, Eur. Phys. J. Plus, 131, 56, 10.1140/epjp/i2016-16056-0 · DOI
  11. Cao, 2020, Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells, Cell, 182, 73, 10.1016/j.cell.2020.05.025 · DOI · Paper page
  12. Chan, 1987, A novel tumour marker related to the c-myc oncogene product, Mol. Cell. Probes, 1, 73, 10.1016/0890-8508(87)90008-9 · DOI
  13. Chi, 2020, Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain, Nat. Commun., 11, 4528, 10.1038/s41467-020-18387-8 · DOI · Paper page
  14. Corti, 2016, Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody, Science, 351, 1339, 10.1126/science.aad5224 · DOI · Paper page
  15. Coughlin, 2012, Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential, Rev. Med. Virol., 22, 2, 10.1002/rmv.706 · DOI · Paper page
  16. Duan, 2009, Human Monoclonal Fab Antibodies Against West Nile Virus and its Neutralizing Activity Analyzed in Vitro and in Vivo, J. Antivir. Antiretrovir., 1, 36, 10.4172/jaa.1000005 · doi:10.4172/jaa.1000005
  17. Emsley, 2010, Features and development of Coot, Acta Crystallogr. D Biol. Crystallogr., 66, 486, 10.1107/S0907444910007493 · DOI · Paper page
  18. Evans, 2013, How good are my data and what is the resolution?, Acta Crystallogr. D Biol. Crystallogr., 69, 1204, 10.1107/S0907444913000061 · DOI · Paper page
  19. Frenzel, 2016, Phage display-derived human antibodies in clinical development and therapy, MAbs, 8, 1177, 10.1080/19420862.2016.1212149 · DOI · Paper page
  20. Frenzel, 2017, Designing Human Antibodies by Phage Display, Transfus. Med. Hemother., 44, 312, 10.1159/000479633 · DOI · Paper page
  21. Hodcroft, 2021, Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677, MedRxiv
  22. Huo, 2020, Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike, Cell Host Microbe, 28, 445, 10.1016/j.chom.2020.06.010 · DOI · Paper page
  23. Jäger, 2013, High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells, BMC Biotechnol., 13, 52, 10.1186/1472-6750-13-52 · DOI · Paper page
  24. Kabsch, 2010, XDS, Acta Crystallogr. D Biol. Crystallogr., 66, 125, 10.1107/S0907444909047337 · DOI · Paper page
  25. Korn, 2020, Baculovirus-free insect cell expression system for high yield antibody and antigen production, Sci. Rep., 10, 21393, 10.1038/s41598-020-78425-9 · DOI
  26. Kreer, 2020, Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients, Cell, 182, 843, 10.1016/j.cell.2020.06.044 · DOI · Paper page
  27. Kretzschmar, 2002, Antibody discovery: phage display, Curr. Opin. Biotechnol., 13, 598, 10.1016/S0958-1669(02)00380-4 · DOI
  28. Kügler, 2015, Generation and analysis of the improved human HAL9/10 antibody phage display libraries, BMC Biotechnol., 15, 10, 10.1186/s12896-015-0125-0 · DOI · Paper page
  29. Kügler, 2018, Construction of Human Immune and Naive scFv Libraries, Methods Mol. Biol., 1701, 3, 10.1007/978-1-4939-7447-4_1 · DOI
  30. Kuhn, 2016, Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display, Proteomics Clin. Appl., 10, 922, 10.1002/prca.201600002 · DOI
  31. Laemmli, 1970, Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature, 227, 680, 10.1038/227680a0 · DOI · Paper page
  32. Li, 2020, High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models, Cell, 183, 429, 10.1016/j.cell.2020.09.007 · DOI · Paper page
  33. Liebschner, 2019, Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix, Acta Crystallogr. D Struct. Biol., 75, 861, 10.1107/S2059798319011471 · DOI · Paper page
  34. Liu, 2020, Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection, bioRxiv
  35. Lu, 2019, Deamidation and isomerization liability analysis of 131 clinical-stage antibodies, MAbs, 11, 45, 10.1080/19420862.2018.1548233 · DOI · Paper page
  36. Lu, 2020, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, 395, 565, 10.1016/S0140-6736(20)30251-8 · DOI · Paper page
  37. Ma, 2021, Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain, J. Virol., 95, e02438-20, 10.1128/JVI.02438-20 · DOI
  38. McCoy, 2007, Phaser crystallographic software, J. Appl. Cryst., 40, 658, 10.1107/S0021889807021206 · DOI · Paper page
  39. Mulangu, 2019, A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics, N. Engl. J. Med., 381, 2293, 10.1056/NEJMoa1910993 · DOI · Paper page
  40. Nakamura, 2017, Effects of a mixture of medetomidine, midazolam and butorphanol on anesthesia and blood biochemistry and the antagonizing action of atipamezole in hamsters, J. Vet. Med. Sci., 79, 1230, 10.1292/jvms.17-0210 · DOI
  41. Nonaka, 2021, Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil, Emerg. Infect. Dis., 27, 1522, 10.3201/eid2705.210191 · DOI · Paper page
  42. Noy-Porat, 2020, A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes, Nat. Commun., 11, 4303, 10.1038/s41467-020-18159-4 · DOI · Paper page
  43. Osterrieder, 2020, Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters, Viruses, 12, 779, 10.3390/v12070779 · DOI · Paper page
  44. Parray, 2020, Identification of an anti-SARS-CoV-2 receptor-binding domain-directed human monoclonal antibody from a naïve semisynthetic library, J. Biol. Chem., 295, 12814, 10.1074/jbc.AC120.014918 · DOI
  45. Pascal, 2018, Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates, J. Infect. Dis., 218, S612, 10.1093/infdis/jiy285 · DOI · Paper page
  46. Rahumatullah, 2017, Antibody-Based Protective Immunity against Helminth Infections: Antibody Phage Display Derived Antibodies against BmR1 Antigen, Int. J. Mol. Sci., 18, 2376, 10.3390/ijms18112376 · DOI
  47. Ranjan, 2021, Bioinformatics analysis of SARS-CoV-2 RBD mutant variants and insights into antibody and ACE2 receptor binding, bioRxiv
  48. Rees-Spear, 2021, The effect of spike mutations on SARS-CoV-2 neutralization, Cell Rep., 34, 108890, 10.1016/j.celrep.2021.108890 · DOI · Paper page
  49. Resende, 2021, A potential SARS-CoV-2 variant of interest (VOI) harboring mutation E484K in the Spike protein was identified within lineage B.1.1.33 circulating in Brazil, Viruses, 13, 724, 10.3390/v13050724 · DOI
  50. Robert, 2014, Deciphering key features in protein structures with the new ENDscript server, Nucleic Acids Res., 42, W320, 10.1093/nar/gku316 · DOI · Paper page
  51. Rondot, 2001, A helper phage to improve single-chain antibody presentation in phage display, Nat. Biotechnol., 19, 75, 10.1038/83567 · DOI · Paper page
  52. Russo, 2018, Parallelized Antibody Selection in Microtiter Plates, Methods Mol. Biol., 1701, 273, 10.1007/978-1-4939-7447-4_14 · doi:10.1007/978-1-4939-7447-4_14
  53. Shields, 2001, High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R, J. Biol. Chem., 276, 6591, 10.1074/jbc.M009483200 · DOI · Paper page
  54. Soltes, 2007, On the influence of vector design on antibody phage display, J. Biotechnol., 127, 626, 10.1016/j.jbiotec.2006.08.015 · DOI
  55. Steinwand, 2014, The influence of antibody fragment format on phage display based affinity maturation of IgG, MAbs, 6, 204, 10.4161/mabs.27227 · DOI · Paper page
  56. Subramanian, 1998, Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group, Pediatr. Infect. Dis. J., 17, 110, 10.1097/00006454-199802000-00006 · DOI · Paper page
  57. Surleac, 2021, Evidence of Novel SARS-CoV-2 Variants Circulation in Romania. AIDS Res Hum Retroviruses, AIDS Res Hum Retroviruses, 37, 329, 10.1089/aid.2021.0009 · DOI
  58. Tian, 2020, Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody, Emerg. Microbes Infect., 9, 382, 10.1080/22221751.2020.1729069 · DOI · Paper page
  59. Trott, 2014, Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody, PLoS ONE, 9, e97478, 10.1371/journal.pone.0097478 · DOI
  60. van Mechelen, 2016, RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors, Antiviral Res., 132, 1, 10.1016/j.antiviral.2016.05.003 · DOI
  61. Walls, 2020, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell, 181, 281, 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
  62. Wan, 2020, Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry, J. Virol., 94, e02015-19, 10.1128/JVI.02015-19 · DOI · Paper page
  63. Wang, 2014, Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins, Biochem. Biophys. Res. Commun., 451, 208, 10.1016/j.bbrc.2014.07.090 · DOI · Paper page
  64. Wang, 2020, A human monoclonal antibody blocking SARS-CoV-2 infection, Nat. Commun., 11, 2251, 10.1038/s41467-020-16256-y · DOI · Paper page
  65. Wenzel, 2020, Human antibodies neutralizing diphtheria toxin in vitro and in vivo, Sci. Rep., 10, 571, 10.1038/s41598-019-57103-5 · DOI
  66. Wenzel, 2020, Antibody Phage Display: Antibody Selection in Solution Using Biotinylated Antigens, Methods Mol. Biol., 2070, 143, 10.1007/978-1-4939-9853-1_8 · doi:10.1007/978-1-4939-9853-1_8
  67. Wrapp, 2020, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, 367, 1260, 10.1126/science.abb2507 · DOI · Paper page
  68. Wu, 2020, A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2, Science, 368, 1274, 10.1126/science.abc2241 · DOI · Paper page
  69. Yan, 2020, Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2, Science, 367, 1444, 10.1126/science.abb2762 · DOI · Paper page
  70. Yuan, 2020, A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV, Science, 368, 630, 10.1126/science.abb7269 · DOI · Paper page
  71. Zeng, 2020, Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy, Antib. Ther., 3, 95
  72. Zhang, 2003, Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library, J. Immunol. Methods, 283, 17, 10.1016/j.jim.2003.07.003 · DOI
  73. Zhou, 2020, Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2, Int. J. Biol. Sci., 16, 1718, 10.7150/ijbs.45123 · DOI · Paper page
  74. Zhou, 2020, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579, 270, 10.1038/s41586-020-2012-7 · DOI · Paper page
  75. Zhu, 2007, Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies, Proc. Natl. Acad. Sci. USA, 104, 12123, 10.1073/pnas.0701000104 · DOI · Paper page

Cited by

See all 96

Metadata

Authors
Bertoglio, F., Fühner, V., Ruschig, M., Heine, P. A., Abassi, L., Klünemann, T., Rand, U., Meier, D., Langreder, N., Steinke, S., Ballmann, R., Schneider, K.-T., Roth, K. D. R., Kuhn, P., Riese, P., Schäckermann, D., Korn, J., Koch, A., Chaudhry, M. Z., Eschke, K., Kim, Y., Zock-Emmenthal, S., Becker, M., Scholz, M., Moreira, G. M. S. G., Wenzel, E. V., Russo, G., Garritsen, H. S. P., Casu, S., Gerstner, A., Roth, G., Adler, J., Trimpert, J., Hermann, A., Schirrmann, T., Dübel, S., Frenzel, A., Van den Heuvel, J., Čičin-Šain, L., Schubert, M., & Hust, M.
Venue
Cell Reports
Publisher
Elsevier BV
Published
2021-07
Volume
36
Issue
4
Pages
109433
ISSN
2211-1247 (ISSN-L)
OpenAlex
W3181438135
Cited by
96
References
27
FWCI
6.14
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.